Mumbai: Sun Pharmaceutical Industries has announced plans to acquire US-based drug maker Organon & Co. in a deal valued at $11.75 billion (approximately ₹97,500 crore), marking one of the largest overseas acquisitions by an Indian pharmaceutical company. The strategic move is expected to significantly boost Sun Pharma’s global footprint and position it among the top 25 pharmaceutical firms worldwide.
The acquisition, once completed, is projected to take the combined entity’s revenue to around $12.4 billion, strengthening its standing in the global pharmaceutical market. The deal is expected to close by 2027, subject to regulatory approvals and other customary conditions.
Strategic push into biosimilars and women’s health
With this acquisition, Sun Pharma aims to enter the rapidly growing biosimilars segment. Biosimilars are highly similar versions of already approved biological medicines, offering comparable safety, efficacy, and quality. This segment is seen as a major growth driver globally due to rising demand for cost-effective biologic treatments.
Organon’s existing portfolio and pipeline are expected to provide Sun Pharma with a strong entry point into this market, helping it diversify beyond its current focus areas.
In addition to biosimilars, the deal will significantly strengthen Sun Pharma’s presence in women’s health—a segment that has been gaining importance globally. Organon has a well-established portfolio in this space, which includes products catering to reproductive health and other therapeutic needs.
Financial details and deal structure
The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon continuing as the surviving entity. Sun Pharma plans to fund the acquisition through a mix of internal cash reserves and committed financing from banks.
For the financial year ended December 31, 2025, Organon reported revenue of $6.2 billion and an adjusted EBITDA of $1.9 billion. The company also had a debt of $8.6 billion and a cash balance of $574 million during the same period.
Organon recently completed the divestiture of a product, receiving an upfront payment of $440 million. The net proceeds from this transaction are expected to strengthen its cash position as of March 31, 2026, which could support the integration process post-acquisition.
Strengthening global position
Industry experts believe that the acquisition will enhance Sun Pharma’s global competitiveness by expanding its product portfolio and geographic reach. Organon’s strong presence in developed markets, particularly in the United States, is expected to complement Sun Pharma’s existing operations.
The move also aligns with Sun Pharma’s long-term strategy of scaling up its specialty and complex generics business while exploring high-growth therapeutic segments.
Challenges and integration outlook
While the deal presents significant growth opportunities, analysts note that integrating a large global company like Organon will come with challenges. Managing debt levels, aligning operational processes, and ensuring regulatory compliance across multiple markets will be key focus areas.
However, Sun Pharma’s experience in handling international acquisitions and its established global presence may help in navigating these complexities.
Conclusion
The proposed acquisition of Organon marks a transformative step for Sun Pharma as it seeks to expand its global footprint and diversify into high-growth segments like biosimilars and women’s health. If successfully executed, the deal could redefine the company’s position in the global pharmaceutical industry, paving the way for sustained long-term growth.
Comments are closed.